Advent Life Sciences United Kingdom

Advent Life Sciences

We invest predominantly in early and mid-stage life sciences companies.  We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.

Real people. Real insight. Real value.

Innovation. Clarity. Execution.

 

 


Dr Dale Pfost
Dr Dale Pfost
LinkedIn logo General Partner 

AFH Holding & Advisory

AFH Holding & Advisory LLC is a boutique investment banking firm that offers financial advisory services. The firm focuses on alternative public offerings marketing strategy planning capital structuring and mergers and acquisitions advisory. Its clientele include Carlisi Natural Gas Inc. Fossil Energy Group LLC Kaikai Technology Co. Ltd. and Yi Xin Copper Co. Ltd. AFH Holding & Advisory LLC is based in Beverly Hills California with an additional office in Pudong China.
Amir Heshmatpour
Founder & Managing Director 

Aisling Capital

Aisling Capital is a private equity group based in New York with over $1.6 billion in assets under management. Aisling is currently looking for new firms for potential investments for the firm?s third fund. The firm looks to make investments in companies seeking to raise a total round of $2-5 million. The firm looks to invest in companies globally with a focus on companies located in the United States.
Dennis Purcell
Founder and Senior Advisor 

Antibody Solutions United States

Antibody Solutions is a premier developer of therapeutic, diagnostic and critical reagent antibodies. Our platforms include human antibodies from transgenic OmniRats™, Hybridoma Libraries™, and high-throughput flow-cytometry screening of cell-associated targets. We provide full technical support and project management with all services performed in the USA. 

Website:
www.antibody.com
Year Founded
1995
Service Provider Type
Medtech Subsector
Biotech Phase of Development
Unique Capabilities

Human Ab producing OmniRats™ 

Hybridoma Libraries™  

High-throughput flow-cytometry screening 

Proven record of success

In Vitro Ab Production

Proven track record of success

John Kenney
President 

ATEM Capital

ATEM Capital manages evergreen Life Sciences investment fund - Health Square Fund (HSF). HSF acts as a consolidator of capital flows from the Emerging Markets and invests into the biotech innovation hubs of the US/Western Europe. HSF's international team combines big-picture business perspective with decades of investment scientific legal portfolio risk management and operational experience. The fund is audited by a Big-4 firm. Our Advisory Board comprises high-caliber entrepreneurs VC veterans and seasoned Wall Street professionals.
Alexey Afanasiev
Executive Partner 
Anton Gopka
CEO General Partner 
Elena Ikhsanova
COO General Partner 

Baxter Ventures

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Priyanka Rohatgi
Director 

Becton Dickinson (BD)

BD (Becton Dickinson and Company) based in Franklin Lakes NJ is a leading medical technology company that partners with customers and stakeholders to address many of the world?s most pressing and evolving health needs. Their innovative solutions are focused on improving drug delivery enhancing the diagnosis of infectious diseases and cancers supporting the management of diabetes and advancing cellular research. The firm has nearly 3 associates in 5 countries who strive to fulfill our purpose of ?Helping all people live healthy lives? by advancing the quality accessibility safety and affordability of healthcare around the world. For more information please visit www.bd.com. BD partners with companies from their formation through to commercialization including expansion of operations and channel access. BD considers a variety of engagement models including research collaborations licenses investments and acquisition when partnering with companies aligned with BD?s core businesses and new areas of strategic interest seeking opportunities from around the globe.
Albert Lauritano
Director Strategic Technology Partnerships 

Biosight, LLC and MIT United States

Biosight, LLC  is a start-up biomedical device company developing a low-cost technology that will enable health care providers (HCPs) to discriminate amongst different types of tissues so that they will no longer need to use the blind and semi-blind approach to procedural instrument placement. The key intellectual capital of Biosight, LLC, (Biosight) is medical procedure needle tip tissue identification using multimodal spectroscopy (MMS) technologies first developed in the Laser Biomedical Research Center (LBRC) at the Massachusetts Institute of Technology. Several founding members of Biosight are the pioneers in this field and have established collaborations with clinicians at the Massachusetts General Hospital to identify clinical areas for this technology. Currently, Biosight, LLC is working with several investors in Massachusetts to further develop the device for numerous clinical applications

Year Founded
2014
Main Sector
Biotech Subsector
Biotech Phase of Development
Medtech Phase of Development
Alliance & Collaborations
Massachusetts Institute of Technology and Massachusetts General Hospital
Current Financing Needs
$10M
IP Status
Application Filed
Recent Milestones
Finalist in MIT 100K Pitch 2014
Management Team Highlights
Harvard and MIT Collaborators
Cheryl Campbell
Cheryl Campbell
LinkedIn logo MIT MBA Student and Intellectual Property Attorney 
BIO

A cancer scientist, corporate/IP lawyer and MBA candidate at the MIT Sloan School of Management who is dedicated to commercializing innovative biopharmaceutical products and medical devices that benefit patients. I have acquired diverse experience in the health care and life sciences industries spanning discovery, commercialization and regulatory development. My goal is to create and execute business and legal strategies that successfully drive products to market and create overall value for patient care. Capabilities include research design, assay development, clinical trial management, market/financial analysis, data modeling, operational design and management, system dynamics, drafting regulations, stakeholder engagement, intellectual property, licensing and contract drafting/negotiations.

BSI Capital Group

BSI Capital is a Single Family Office based in Mexico City Mexico. The firm is looking to make growth stage investments into healthcare companies generally in series C and D rounds or later. Due to the structure of the firm BSI has a highly variable investment size that will depend of the financial needs of the company. The firm is currently looking for new opportunities throughout the United States Mexico and Canada. The firm has no set number of investment in plans to make over the next 6-9 months.
Alejandra Paradones
CEO & Founder